We are led by a team of seasoned experts in the field of microbiome research dedicated to the treatment and prevention of disease through therapeutics that target the interactions between the human host and the trillions of microbiota that make up the microbiome.
Chief Executive Officer
Graham Waters is a healthcare industry professional with over 30 years’ experience who has held both strategic and operational roles, creating and implementing growth strategies internationally. He has worked for Warner-Lambert, Mundipharma, and Pharmacia. His experience spans prescription pharmaceuticals, over- the- counter medicines, medical foods, pharmaceutical excipients and novel APIs on a global scale. A key highlight of Graham’s career was the development of the smoking cessation category as it evolved into a multi billion dollar healthcare market sector.
Graham joined Clasado Biosciences as Group CEO in 2004, and under his leadership the Company focused on developing its understanding of the human gut microbiome, paving the way for HOST’s work developing therapeutics targeting the interactions between the human host and the microbiome.
Head, Global Regulatory Affairs
Kevin Chapman brings over 25 years of experience as a regulatory professional to his current role at HOST Therabiomics. Prior to joining HOST in October 2016, Kevin held positions at GlaxoSmithKline, Amgen, Covance, Shire, Barrier Therapeutics, Wyeth, Pfizer and BTG. His responsibilities included management of complex projects and the global regulatory teams involved in product development that covered different therapeutic areas such as CNS, haematology/oncology, inflammation and transplant therapies, anti-infectives/anti-virals, metabolic disorders, cardiovascular disease, respiratory disease, gastro-intestinal disorders, and dermatological conditions.
Kevin’s biopharmaceutical development experience covers small molecule and biotechnology products providing strategic input from the early development phase, regulatory review, through to post-licensing activities.
Head of Finance
Jon Boleat has more than 15 years of experience in finance, focused within the banking, assurance and advisory services, and biotechnology industries. Prior to joining HOST, he held progressively senior roles within Ernst & Young’s assurance divisions in the UK and recently in Wellington, New Zealand. During this time Jon was responsible for leading and managing large teams providing assurance services to both the public and private sectors, with a focus on the financial services industry.
Brett Sousa, MBA
Head of Corporate Strategy and Commercial Development
As a biotechnology professional with 14 years of industry experience, Brett has held positions in commercial, corporate and business development, corporate strategy, and strategic operations functions. In his current role, Brett leads all corporate strategy initiatives and develops commercial strategies for HOST’s lead drug development programs.
Prior to joining HOST Therabiomics, he worked as Director of Commercial Assessment at Shire where he was responsible for performing commercial due diligence for licensing, mergers and acquisitions, and aligning immunology and neuroscience disease area strategies with the broader corporate strategy. Before working at Shire, Brett held roles of increasing responsibility at Biogen and Sanofi.
Brett holds a B.A. in English and Psychology from Amherst College and an MBA from the Boston University Questrom School of Business.